"Od 1995 r. w naszym prywatnym centrum medycznym zajmujemy się diagnozowaniem i udzielaniem konsultacji lekarskich pacjentom oraz prowadzimy badania kliniczne, a od 2018 r. stanowimy część największej w Polsce sieci ośrodków badań klinicznych (SMO) Pratia. Stworzyliśmy świetnie zorganizowany zespół oddanych pacjentom lekarzy-badaczy, wykwalifikowanych pielęgniarek i farmaceutów oraz energicznych i skrupulatnych koordynatorów. Stale modernizując zaplecze, zdobywając doświadczenie i doskonaląc nasza jakość, zwiększamy liczbę programów oraz pacjentów."

During the past decade, Pratia MCM Krakow conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 12 clinical trials were completed, i.e. on average, 18.5% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 12 clinical trials were completed. i.e. 26.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pratia MCM Krakow" #1 sponsor was "Janssen Research & Development, LLC" with 11 trials, followed by "Loxo Oncology, Inc." with 5 trials sponsored, "Pfizer" with 5 trials sponsored, "Genmab" with 3 trials sponsored and "Incyte Corporation" with 3 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pratia MCM Krakow" #1 collaborator was "Eli Lilly and Company" with 6 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "ICON Clinical Research" with 2 trials as a collaborator, "Pharmacyclics LLC." with 2 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Pratia MCM Krakow" are "Chronic Lymphocytic Leukemia" (10 trials), "Small Lymphocytic Lymphoma" (7 trials), "Rheumatoid Arthritis" (6 trials), "Follicular Lymphoma (FL)" (4 trials) and "Leukemia, Lymphocytic, Chronic, B-Cell" (4 trials). Many other conditions were trialed in "Pratia MCM Krakow" in a lesser frequency.

Most popular intervention types in "Pratia MCM Krakow" are "Drug" (58 trials), "Biological" (10 trials), "Other" (3 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Rituximab" (9 trials), "Ibrutinib" (6 trials), "Pirtobrutinib" (5 trials) and "Bendamustine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Pratia MCM Krakow" are 63 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Pratia MCM Krakow". undefined are not yet recruiting, 26 are recruiting, 19 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 17 completed trials in Pratia MCM Krakow, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Pratia MCM Krakow, 16 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".